NPI: 1538214275 · NORFOLK, VA 23517 · Pediatrics Physician · NPI assigned 01/24/2007
Authorized official ABSHIRE, KATHRYN controls 20+ related entities in our dataset. Read more
| Authorized Official | ABSHIRE, KATHRYN (SENIOR VP/CFO) |
| Parent Organization | CHILDRENS MEDICAL GROUP INC |
| NPI Enumeration Date | 01/24/2007 |
Other providers sharing the same authorized official: ABSHIRE, KATHRYN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 10,042 | $406K |
| 2019 | 20,913 | $765K |
| 2020 | 20,074 | $685K |
| 2021 | 22,740 | $748K |
| 2022 | 21,651 | $751K |
| 2023 | 24,360 | $805K |
| 2024 | 18,241 | $688K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 25,128 | 22,857 | $1.53M |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 9,955 | 9,475 | $812K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 8,646 | 7,213 | $666K |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 6,359 | 5,837 | $561K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 5,926 | 5,771 | $483K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 2,043 | 2,005 | $183K |
| 90686 | 9,108 | 8,597 | $108K | |
| 92551 | 7,810 | 7,527 | $81K | |
| 90670 | 3,323 | 3,040 | $66K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 7,052 | 5,567 | $64K |
| 90698 | 3,025 | 2,744 | $46K | |
| 96127 | 7,032 | 6,324 | $37K | |
| 90677 | 569 | 550 | $23K | |
| 90671 | 770 | 753 | $18K | |
| 90680 | 1,057 | 986 | $16K | |
| 96161 | 6,574 | 6,142 | $16K | |
| 90697 | 772 | 751 | $15K | |
| 99174 | 2,615 | 2,523 | $14K | |
| 99188 | 629 | 592 | $14K | |
| 90651 | 417 | 394 | $12K | |
| 99173 | 3,854 | 3,730 | $10K | |
| 90656 | 498 | 495 | $9K | |
| 90633 | 725 | 696 | $9K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 420 | 191 | $6K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 148 | 141 | $6K |
| 83655 | 442 | 421 | $5K | |
| 90744 | 441 | 397 | $5K | |
| 85018 | 2,014 | 1,913 | $5K | |
| 1128F | 11,720 | 10,900 | $4K | |
| 90685 | 430 | 346 | $4K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 218 | 179 | $3K |
| 91321 | 75 | 65 | $2K | |
| 90734 | 126 | 119 | $2K | |
| 99000 | 1,201 | 1,130 | $2K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 54 | 54 | $2K |
| 36416 | 2,653 | 2,473 | $1K | |
| 1127F | 2,045 | 1,928 | $825.00 | |
| 0001A | 20 | 20 | $778.80 | |
| 0071A | 17 | 17 | $727.20 | |
| 90688 | 71 | 70 | $706.71 | |
| 0002A | 19 | 18 | $686.40 | |
| 90710 | 12 | 12 | $637.85 | |
| 0072A | 14 | 14 | $636.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 26 | 25 | $451.65 |
| 96160 | 147 | 143 | $343.08 | |
| 90696 | 12 | 12 | $231.77 | |
| 90707 | 13 | 12 | $135.85 | |
| 90716 | 13 | 12 | $135.85 | |
| 90715 | 12 | 12 | $133.65 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 13 | 12 | $1.12 |
| 91300 | 39 | 38 | $0.32 | |
| G9920 | Screening performed and negative | 79 | 77 | $0.00 |
| G8431 | Screening for depression is documented as being positive and a follow-up plan is documented | 12 | 12 | $0.00 |
| 91307 | 14 | 14 | $0.00 | |
| G8510 | Screening for depression is documented as negative, a follow-up plan is not required | 1,614 | 1,543 | $0.00 |